You're right about investors needing to understand the risks of Biotechs. But, investors have a RIGHT to expect intelligent management and some management concern about longs who have been the backbone of this company.
At this point you look like a genius with those 5% CD's!
Unfortunately for me (at this time), when Stoll replaced Simmons, I thought we had finally gotten the star management.